Home  »  Companies   »  Here are the top Institutional holders of Catalyst...

Here are the top Institutional holders of Catalyst Biosciences Inc. (CBIO) shares

113 institutions hold shares in Catalyst Biosciences Inc. (CBIO), with 1.01M shares held by insiders accounting for 3.24% while institutional investors hold 58.60% of the company’s shares. The shares outstanding are 30.80M, and float is at 26.27M with Short Float at 4.34%. Institutions hold 56.71% of the Float.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 1.87 million shares valued at $11.77 million. The investor’s holdings represent 5.95% of the CBIO Shares outstanding. As of Dec 30, 2020, the second largest holder is Acuta Capital Partners LLC with 1.36 million shares valued at $8.57 million to account for 4.33% of the shares outstanding. The other top investors are Blackrock Inc. which holds 1.35 million shares representing 4.30% and valued at over $8.5 million, while Vanguard Group, Inc. (The) holds 3.14% of the shares totaling 0.98 million with a market value of $6.2 million.

Catalyst Biosciences Inc. (NASDAQ: CBIO) is -18.70% lower on its value in year-to-date trading and has touched a low of $4.05 and a high of $8.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CBIO stock was last observed hovering at around $4.95 in the last trading session, with the day’s gains setting it 0.18% off its average median price target of $16.00 for the next 12 months. It is also 79.48% off the consensus price target high of $25.00 offered by 5 analysts, but current levels are 65.8% higher than the price target low of $15.00 for the same period.

Currently trading at $5.13, the stock is 3.09% and -8.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.42 million and changing 3.64% at the moment leaves the stock -8.66% off its SMA200. CBIO registered -15.90% loss for a year compared to 6-month loss of -10.31%. The firm has a 50-day simple moving average (SMA 50) of $5.91 and a 200-day simple moving average (SMA200) of $5.82.

The stock witnessed a 3.85% gain in the last 1 month and extending the period to 3 months gives it a -10.78%, and is 3.01% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.56% over the week and 5.17% over the month.

Catalyst Biosciences Inc. (CBIO) has around 36 employees, a market worth around $151.90M and $20.90M in sales. Distance from 52-week low is 26.67% and -37.59% from its 52-week high.

Catalyst Biosciences Inc. (CBIO) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Catalyst Biosciences Inc. (CBIO) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 1 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Catalyst Biosciences Inc. is expected to release its quarterly report on 08/05/2021 and quarterly earnings per share for the current quarter are estimated at -$0.64 with sales reaching $730k over the same period.The EPS is expected to grow by 36.20% this year, but quarterly earnings will post -85.30% year-over-year. Quarterly sales are estimated to shrink -95.50% in year-over-year returns.

Catalyst Biosciences Inc. (CBIO) Insider Activity

A total of 13 insider transactions have happened at Catalyst Biosciences Inc. (CBIO) in the last six months, with sales accounting for 0 and purchases happening 13 times.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Catalyst Biosciences Inc. (CBIO): Who are the competitors?

The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 2.18% up over the past 12 months. AbbVie Inc. (ABBV) is 35.25% up on the 1-year trading charts. Short interest in the company’s stock has fallen -44.19% from the last report on Apr 14, 2021 to stand at a total of 1.14 million short shares sold with a short interest ratio of 3.51.

Related Posts

110500

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam